Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

16.18 -0.09 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider. 
Via InvestorPlace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
ACAD stock results show that ACADIA Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
Via InvestorPlace
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
From Acadia Pharmaceuticals Inc.
Via Business Wire
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
Why Are Airline Stocks Down Today?
Airline stocks are down on Tuesday as investors deal with several bits of bad news for the industry on Tuesday! 
Via InvestorPlace
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals stock is falling on Tuesday as investors in ACAD react to its failed Phase 3 clinical trial of pimavanserin. 
Via InvestorPlace
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
The company says it doesn't plan to further develop Nuplazid in clinical testing. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fis 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday! 
Via InvestorPlace
Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details
Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial results on pimavanserin for schizophrenia-negative symptoms. Insights on efficacy, safety, and future considerations. 
Via Benzinga
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.